Paradromics
PrivateLast Round
Strategic
Feb 12, 2025
Total Funding Raised
$84.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Paradromics is a neurotechnology company that develops advanced brain-computer interface technology to enhance data transmission rates between the brain and machines, facilitating high-volume, bidirectional data streaming for patients with neurological disorders.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials, Health IoT
Business Model
B2B
Customer Profile
Hardware Sales, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Paradromics Comparables
Compare Paradromics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Tether | 89% | |
| Precision Neuroscience | 87% | |
| Neuralink | 86% |
Paradromics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Feb 12, 2025 | ||||
| Series A | May 18, 2023 | ||||
| Grant | Oct 14, 2021 | ||||
| Seed | Jul 22, 2021 | ||||
| Seed | Jun 11, 2018 | ||||
Grant | Jul 10, 2017 |
Key People
Founding team and executive leadership
Paradromics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Loup Funds | Seed |
| National Institute of Mental Health | Grant |
| Fusion Fund | Seed |
| Dolby Family Ventures | Seed, Strategic, Series A |
| IT-Farm Corporation | Seed, Strategic |
| NIH RADx | Grant |
| Tech-Synergy | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 24, 2026
Monthly visitors increased 39% MoM.
- Mar 18, 2026
Launched an academic collaboration programme to advance BCI technology.
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
Paradromics is developing BCI platform.
- identified_as_competitor_ofAug 27, 2026
Paradromics identified as competitor of Synchron, Inc..
- is_developingAug 26, 2026
Paradromics is developing high-bandwidth neural interface technology on Aug 26th '26.
- hiresJul 7, 2026
Paradromics Inc hired William J. Marks Jr. as chief clinical officer on Jul 7th '26.
Paradromics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Paradromics's valuation, stock price, and market status.
Is Paradromics a public or private company?
Paradromics is a private company.
What is the current stock price of Paradromics?
Paradromics is a private company with no public stock price. No recent secondary market data is available.
How much is Paradromics worth (valuation)?
Valuation information for Paradromics is not publicly available.
Can I buy Paradromics stock?
Paradromics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Paradromics's last funding round?
Paradromics's most recent funding round was Strategic on February 12, 2025.
Who are the main investors in Paradromics?
Key investors in Paradromics include NIH RADx, Tech-Synergy, Synergy Ventures, Arkitekt Ventures, Prime Movers Lab.
Will Paradromics IPO soon?
No public IPO plans have been announced for Paradromics.
How can I track Paradromics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Paradromics's secondary market activity and sign up for updates.